Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Chancellor

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Molecular Pharmaceutics|August 8, 2006
Recent advances in intravesical drug/gene deliveryPradeep Tyagi, Pao-Chu Wu, Michael Chancellor, et al.
The Journal of Urology|November 23, 2016
Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive BladderPradeep Tyagi, Mahendra Kashyap, Naoki Yoshimura, et al.
European Urology Focus|July 4, 2020
Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic ReviewMohammad Abrar, Nisha Pindoria, Sachin Malde, et al.
Molecular Pharmaceutics|August 8, 2006
Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugatesPradeep Tyagi, Rajkumar Banerjee, Soumitra Basu, et al.
Medicine|July 27, 2023
Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impactVictor Nitti, Cornelia Haag-Molkenteller, Michael Kennelly, et al.
Lower Urinary Tract Symptoms|December 15, 2015
Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome PatientsKenneth M Peters, Nirmal Jayabalan, Don Bui, et al.
Scientific Reports|April 7, 2021
Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placeboYuan-Chi Shen, Pradeep Tyagi, Wei-Chia Lee, et al.
Neurourology and Urodynamics|April 8, 2015
Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivityEmmanuel Chartier-Kastler, Eric Rovner, Zsolt Hepp, et al.
The Journal of Urology|April 17, 2012
Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitisPradeep Tyagi, Kim Killinger, Vikas Tyagi, et al.
ISRN Pharmacology|February 15, 2014
Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndromePradeep Tyagi, Mahendra P Kashyap, Naoki Kawamorita, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Molecular Pharmaceutics|August 8, 2006
Recent advances in intravesical drug/gene deliveryPradeep Tyagi, Pao-Chu Wu, Michael Chancellor, et al.
The Journal of Urology|November 23, 2016
Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive BladderPradeep Tyagi, Mahendra Kashyap, Naoki Yoshimura, et al.
European Urology Focus|July 4, 2020
Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic ReviewMohammad Abrar, Nisha Pindoria, Sachin Malde, et al.
Molecular Pharmaceutics|August 8, 2006
Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugatesPradeep Tyagi, Rajkumar Banerjee, Soumitra Basu, et al.
Medicine|July 27, 2023
Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impactVictor Nitti, Cornelia Haag-Molkenteller, Michael Kennelly, et al.
Lower Urinary Tract Symptoms|December 15, 2015
Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome PatientsKenneth M Peters, Nirmal Jayabalan, Don Bui, et al.
Scientific Reports|April 7, 2021
Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placeboYuan-Chi Shen, Pradeep Tyagi, Wei-Chia Lee, et al.
Neurourology and Urodynamics|April 8, 2015
Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivityEmmanuel Chartier-Kastler, Eric Rovner, Zsolt Hepp, et al.
The Journal of Urology|April 17, 2012
Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitisPradeep Tyagi, Kim Killinger, Vikas Tyagi, et al.
ISRN Pharmacology|February 15, 2014
Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndromePradeep Tyagi, Mahendra P Kashyap, Naoki Kawamorita, et al.
Pageof 6